Physicians 2017-09-11T10:24:41+00:00

The PreludeDx DCIS Test That Enables Personalized Treatment

Contact Us

DCISionRT: THE PreludeDx TEST FOR DCIS

DCISionRT was developed specifically to address the challenging decision patients diagnosed with DCIS and their physicians face when determining treatment following breast conserving surgery. Now you can make decisions with biological insight not previously available.

INTELLIGENT RISK ALGORITHMS

DCISionRT is the first biological risk signature designed specifically for DCIS. Two intelligent algorithms are used, one to predict progression to invasive breast cancer and another to predict any type of recurrence (DCIS or invasive breast cancer).

EASY INTEGRATION INTO CLINICAL PRACTICE

DCISionRT’s intelligent risk algorithms assess biologic risk in combination with clinical and pathologic factors physicians rely on. PreludeDx’s integrated approach provides physicians the confidence they need when implementing a new biological risk profile into their practice.

ROBUST DEVELOPMENT & CLINICAL EVIDENCE

The development of DCISionRT included 1,079 patients with DCIS across multiple leading cancer research institutions. The first independent validation of DCISionRT included 455 patients demonstrating significant prognostic utility for patients treated with breast conserving surgery and optional radiation therapy. Two ongoing prospective clinical validation studies, including an additional 1,500 patients, are scheduled for completion in early 2017.

RISK ASSESSMENT YOU CAN COUNT ON

PreludeDx has developed a reliable system to accurately provide patients a risk assessment—something that has been previously unavailable until now.

DCISionRT has been clinically validated in female patients, greater than 26 years old, diagnosed with DCIS. These women had no prior invasive breast cancer or in situ breast cancer.
Contact us at info@preludedx.com for information about availability of DCISionRT.